Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
| 8.47 BATS BZX Real-Time Price As of 3:55pm ET |  +0.015 / +0.18%Today’s Change | 6.78 Today|||52-Week Range 11.34 | +5.68% Year-to-Date |
Latest TEVA News | Press Releases
| Is Prometheus Biosciences a Good Stock to Buy Right Now? 5:32am / MotleyFool.com - Paid Partner Content | Emergent (EBS) OTC Narcan Filing Gets FDA Priority Review Tag Dec 07 / Zacks.com - Paid Partner Content |
| 4 Stocks to Buy Before the Next Big Bull Rally Dec 08 / StockNews.com - Paid Partner Content | 3 Unparalleled Stocks to Buy That Have Never Been This Cheap Dec 05 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 8.45 |
| Today’s open | 8.47 |
| Day’s range | 8.25 - 9.08 |
| Volume | 12,099,875 |
| Average volume (3 months) | 10,372,153 |
| Market cap | $9.6B |
Data as of 3:55pm ET, 12/09/2022
Growth & Valuation
| Earnings growth (last year) | -- |
| Earnings growth (this year) | -2.21% |
| Earnings growth (next 5 years) | +2.84% |
| Revenue growth (last year) | -4.87% |
| P/E ratio | NM |
| Price/Sales | 0.56 |
| Price/Book | 0.93 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| BBIOBridgeBio Pharma Inc | -0.31 | -3.35% |
| OASMYVivesto AB | 0.00 | 0.00% |
| ---- | ||
| IMMBImmunotech Laborator... | 0.00 | 0.00% |
Data as of 3:55pm ET, 12/09/2022
Financials
| Next reporting date | February 15, 2023 |
| EPS forecast (this quarter) | $0.71 |
| Annual revenue (last year) | $15.8B |
| Annual profit (last year) | $417.0M |
| Net profit margin | 2.63% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Generic |
No executives to display |
Corporate headquarters Tel Aviv, Tel Aviv |
Forecasts
